Objective To explain discrepant findings for fluoxetine's efficacy in three influential network meta-analyses (NMAs) of treatments for pediatric depression, which led to conflicting clinical recomme.....

Modern studies find that fluoxetine has lost its efficacy for children and can now be considered clinically equivalent to placebo.

BackgroundReliable diagnosis is a cornerstone of medical practice, yet concerns about diagnostic reliability have long haunted psychiatry. In the 1970s, the ...

Karl Mathiesen’s article in The Observer on ADHD rightly draws attention to people who are struggling, sometimes severely, as well as to unacceptable delays in receiving help.

Science is supposed to be self-correcting. But what happens when the journals entrusted to uphold this principle become its gatekeepers?

Neither genetics nor brain scans can distinguish a person with depression, A.D.H.D. or autism from one without.

Blog encouraging critical debate about psychiatry

Dr Max Pemberton isn’t uncompassionate or especially radical, but he assembles a team of medics whose stance on the condition is clear from the off. This is a documentary that will incense and offend ...

The culture war over ADHD is based on a misunderstanding of what a psychiatric diagnosis actually means.

Fluoxetine’s efficacy estimates in pediatric depression trials have declined to the range of placebo equivalence. We investigated whether changes in t…

YouTube video by COURT TV

Background The COVID-19 pandemic significantly impacted the mental health of children and adolescents, particularly those from low-income families and adolescent girls. The long-term effects remain unclear. This study assessed the mental health measured by emotional and behavioural problems and quality of life (QoL) among German children and adolescents, emphasising socio-economic status and gender differences. The help-seeking behaviour among families of children with mental health problems was also examined. Methods A nationwide representative online survey was conducted in April/May 2024. N = 1,530 children and adolescents (ages 8–17) and their parents participated. The self- and parent-report survey assessed behavioural and emotional problems (Strength and Difficulties Questionnaire). QoL (KIDSCREEN-10 Index) was rated in self-report. Parents reported on past help-seeking behaviour within and outside of school via items constructed for the present study. Results Behavioural and emotional problems (21.1% in self-report, 22.4% in parental report) and low QoL (27.3%) were higher than pre-pandemic levels. Children from low-income families were particularly affected. Of all parents, 23.7% reported a need for help due to their child’s mental health issues in the last 12 months, with 28.4% of these parents not seeking professional support. Among those who sought help, most contacted multiple services, with teachers, psychotherapists and general practitioners being the most frequently contacted services. Families who secured a therapy placement waited an average of 12 weeks for an initial appointment and 18 weeks to begin therapy. Conclusions Behavioural and emotional problems as well as low QoL seem to stabilise at a rate higher than the pre-pandemic baseline, indicating a need for ongoing monitoring, adjustment to the mental health system and further research on correlates and causes of this stabilisation.

Neurodiversity has offered many people dignity and belonging, but its emphasis on neurological differences reproduces the problematic assumptions of the medical model.

Podcast-Folge · The Daily · 22. Juni · 32 Min.

As provision of basic needs continues to atrophy, resistance increasingly takes an individualised, myopic form.

Major depressive disorder (MDD) is often resistant to standard antidepressant therapy. Inflammation has been implicated in MDD pathophysiology and inf…

Depressionen, Angststörungen, ADHS: Therapien und Diagnosen sickern in unsere Alltagskultur ein. Für Betroffene fällt so zumindest der Druck des Stigmas langsam weg. Die Psychologisierung der Welt bir...

The drug was found to be more likely to cause suicidality than relief from anxiety. This approval demonstrates everything that is wrong with the FDA approval system and should be reversed.

The approval is an example of what can go wrong in "evidence-based" psychiatry due to placing guild interests before patient safety.